|
Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease Clinical research trials and Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease. Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease clinical trial. Participants frequently obtain the most expert healthcare available for their Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease  Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease
Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease
For Condition: Parkinson Disease
Status: No longer recruiting
Sponsor(s): FDA Office of Orphan Products Development , Memorial Hospital of Rhode Island
Synopsis: OBJECTIVES: I. Determine the efficacy and tolerability of clozapine in ameliorating psychosis in patients with idiopathic Parkinson's disease (PD). II. Determine the adverse effects of clozapine on motor function in this patient population. III. Determine the safety of clozapine in psychotic PD patients taking multiple anti-PD medications. IV. Describe the phenomenology of drug induced psychosis in PD.
Details: PROTOCOL OUTLINE: This is a randomized, placebo controlled, double blind study, followed by an open label treatment of all patients. Patients are stratified according to the institutional investigator and age. In the first phase of the study, patients receive either clozapine or placebo. The drug is taken orally at night, approximately 30 minutes before retiring. Therapy continues for 4 weeks unless psychosis becomes unmanageable without hospitalization, parkinsonism worsens, or other adverse effects occur. It is possible that the dose may be escalated. In the second phase of the study, all patients are treated with open label clozapine. Therapy continues for 3 months unless psychiatric status or parkinsonism progress. Dose escalation is also possible during this phase. Patients are followed weekly during the first phase of the study, and monthly during the second phase.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Presumed idiopathic Parkinson's disease Presence of three of the cardinal features: Rest tremor Rigidity Bradykinesias/akinesia Postural and balance abnormalities Absence of alternative explanations for the syndrome Absence of atypical features Psychosis of at least 4 weeks duration requiring treatment --Prior/Concurrent Therapy-- Chemotherapy: No concurrent chemotherapy Other: No use of any dopamine blocking drug within the past 3 months No use of depot neuroleptic within the past 12 months No change of antidepressant or anxiolytic dose within the past 1 month No prior clozapine for psychosis Anti-PD medications stable for at least 7 days before study entry --Patient Characteristics-- Hematopoietic: No history of leukopenia No active blood dyscrasia other than mild anemia Renal: No active problems with urinary retention Cardiovascular: No symptomatic orthostatic hypotension No uncontrolled angina No myocardial infarction within the past 3 months Other: Fertile patients must use effective contraception No uncontrolled seizures (i.e., 1 or more seizures per month over the past 6 months) No dementia precluding accurate assessment on psychiatric assessment battery No AIDS No other illness that would make use of clozapine potentially hazardous No narrow angle glaucoma No systemic factor contributing to the psychosis (e.g., urinary infection, liver disease, renal failure, anemia, infection, etc.)
Total Enrollment: 60
Location and Contact Information:
Overall Study Official:
JosephFriedman, Study Chair, Memorial Hospital of Rhode Island
Additional Information:
Study ID Numbers: 199/13295; MHRI-FDR001416
Study Start Date: October 1993
Record last reviewed: May 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004826
Other Parkinson Disease Studies:
1. A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease
2. An Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability, and Therapeutic Response In Patients with Parkinson's Disease with an Investigational Drug
3. Study of LY300164 for the Treatment of Parkinson's Disease
4. Chinese Exercise Modalities in Parkinson's Disease
5. Phase II Study of Pallidotomy for Parkinson Disease
Related Studies:
Other Parkinson Disease Clinical Trials
Other Clinical Trials
Other Clinical Trials
Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease
|
|
|
|
|
|
|
|
